Fusion Pharmaceuticals Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
106
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2.19B
Fusion Pharmaceuticals General Information
Description
Manufacturer of radiopharmaceuticals focused on developing next-generation radiopharmaceuticals as precision medicines. The company specializes in targeted alpha therapeutics using proprietary linker technology to improve the safety and efficacy of radiopharmaceuticals, thereby enhancing the lives of cancer patients.
Contact Information
Website
www.fusionpharma.com(Operating Subsidiary)
Corporate Office
- 270 Longwood Road South
- Hamilton, Ontario L8P 0A6
- Canada
Corporate Office
- 270 Longwood Road South
- Hamilton, Ontario L8P 0A6
- Canada
Fusion Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 04-Jun-2024 | $2.19B | Completed | Generating Revenue | ||
| 6. PIPE | 28-Feb-2023 | Completed | Generating Revenue | |||
| 5. IPO | 26-Jun-2020 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 25-Mar-2019 | Completed | Startup | |||
| 3. Early Stage VC (Series A) | 25-Sep-2017 | Completed | Startup | |||
| 2. Seed Round | 09-Jan-2016 | Completed | Startup | |||
| 1. Spin-Off | 22-Dec-2014 | Completed | Startup |
Fusion Pharmaceuticals Comparisons
Industry
Financing
Details
Fusion Pharmaceuticals Competitors (67)
One of Fusion Pharmaceuticals’s 67 competitors is Compass Therapeutics, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Compass Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Ratio Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Ariceum | Venture Capital-Backed | Berlin, Germany | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Kymera Therapeutics | Formerly VC-backed | Watertown, MA |
Fusion Pharmaceuticals Patents
Fusion Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024404739-A1 | Psma-targeted radiopharmaceuticals for treatment of cancer | Pending | 18-Dec-2023 | ||
| EP-4827938-A1 | Psma-targeted radiopharmaceuticals for treatment of cancer | Pending | 18-Dec-2023 | ||
| WO-2025129334-A1 | Psma-targeted radiopharmaceuticals for treatment of cancer | Inactive | 18-Dec-2023 | ||
| AU-2024298849-A1 | Psma-targeted radiopharmaceuticals for treatment of cancer | Pending | 27-Jul-2023 | ||
| EP-4750498-A1 | Psma-targeted radiopharmaceuticals for treatment of cancer | Pending | 27-Jul-2023 | A61K47/12 |
Fusion Pharmaceuticals Signals
Fusion Pharmaceuticals Former Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adams Street Partners | PE/Buyout | Minority | ||
| Avidity Partners | Asset Manager | Minority | ||
| CPP Investments | Asset Manager | Minority | ||
| Centre For Probe Development And Commercialization | Corporation | |||
| FACIT | Venture Capital | Minority |
Fusion Pharmaceuticals Investments & Acquisitions (4)
Fusion Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with RadioMedix (225Ac-PSMA I&T Program). The deal was made on 13-Feb-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| RadioMedix (225Ac-PSMA I&T Program) | 13-Feb-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Rainier Therapeutics (Vofatamab) | 01-Sep-2022 | Corporate Asset Purchase | Buildings and Property | ||
| MediaPharma | 31-Dec-2021 | Merger/Acquisition | Drug Discovery | ||
| Ipsen (IPN-1087) | 01-Apr-2021 | Corporate Asset Purchase | Buildings and Property |
Fusion Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Fusion Pharmaceuticals FAQs
-
When was Fusion Pharmaceuticals founded?
Fusion Pharmaceuticals was founded in 2014.
-
Where is Fusion Pharmaceuticals headquartered?
Fusion Pharmaceuticals is headquartered in Hamilton, Canada.
-
What is the size of Fusion Pharmaceuticals?
Fusion Pharmaceuticals has 106 total employees.
-
What industry is Fusion Pharmaceuticals in?
Fusion Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Fusion Pharmaceuticals a private or public company?
Fusion Pharmaceuticals is a Private company.
-
What is the current valuation of Fusion Pharmaceuticals?
The current valuation of Fusion Pharmaceuticals is .
-
What is Fusion Pharmaceuticals’s current revenue?
The current revenue for Fusion Pharmaceuticals is .
-
How much funding has Fusion Pharmaceuticals raised over time?
Fusion Pharmaceuticals has raised $444M.
-
Who are Fusion Pharmaceuticals’s investors?
Adams Street Partners, Avidity Partners, CPP Investments, Centre For Probe Development And Commercialization, and FACIT are 5 of 20 investors who have invested in Fusion Pharmaceuticals.
-
Who are Fusion Pharmaceuticals’s competitors?
Compass Therapeutics, Ratio Therapeutics, Ariceum, NGM Biopharmaceuticals, and Kymera Therapeutics are some of the 67 competitors of Fusion Pharmaceuticals.
-
When was Fusion Pharmaceuticals acquired?
Fusion Pharmaceuticals was acquired on 04-Jun-2024.
-
Who acquired Fusion Pharmaceuticals?
Fusion Pharmaceuticals was acquired by AstraZeneca.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process